Mobile

A randomized, open-label, phase II maintenance study in patients with EGFR mutated, metastatic non-small-cell lung cancer who progressed after treatment with afatinib as first EGFR-targeting agent fo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001983-36

A randomized, open-label, phase II maintenance study in patients with EGFR mutated, metastatic non-small-cell lung cancer who progressed after treatment with afatinib as first EGFR-targeting agent followed by a platinum-based induction chemotherapy Eine randomisierte, offene Phase II - Studie zur Fortführung der pan-ERBB Blockade nach einer platinbasierten Induktionschemotherapie bei Patienten mit metastasiertem, EGFR mutiertem, nicht-kleinzelligen Lungenkarzinom mit Progress nach Behandlung mit Afatinib als erste gegen den EGFR gerichtete Therapie

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer progressing after treatment with afatinib as first tyrosine kinase inhibitor with respect to progression-free survival

Critère d'inclusion

  • Patients with stage IIIB or IV metastatic non-small-cell lung cancer with somatic EGFR mutation

Liens